Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition

Journal of Infectious Diseases

Volumn 194, Issue 1, 2006, Pages 42-52

  Wald, Anna ^a,b   Krantz, Elizabeth ^a   Selke, Stacy ^a   Lairson, Ellen ^a   Morrow, Bhoda Ashley ^a   Zeh, Judy ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AWARENESS; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 2; HUMAN; INCUBATION TIME; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SEXUALITY; VIRUS INFECTION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; DISCLOSURE; FEMALE; HERPES GENITALIS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SEXUAL BEHAVIOR; SEXUAL PARTNERS; TIME FACTORS;

EID: 33745192537     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/504717     Document Type: Article

References (50)

1. Fleming D, McQuillan G, Johnson R, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-11.
2. Armstrong GL, Schillinger J, Markowitz L, et al. Incidence of herpes simplex virus type 2 infection in the United States. Am J Epidemiol 2001; 153:912-20.
3. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis 1985; 12:33-9.
4. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20.
5. Wald A, Langenberg A, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285:3100-6.
6. Corey L, Wald A. Genital herpes. In: Holmes KK, Sparling PF, Mardh P-A, et al., eds. Sexually transmitted diseases. 3rd ed. New York: McGraw-Hill, 1999.
7. Blank H, Haines H. Experimental human reinfection with herpes simplex virus. J Invest Dermatol 1973; 61:223-5.
8. Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51(RR-6):1-78.
9. Ashley-Morrow R, Krantz E, Wald A. Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2. Sex Transm Dis 2003; 30:310-4.
10. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (Immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988; 26:662-7.
11. Lafferty WE, Krofft S, Remington M, et al. Diagnosis of herpes simplex virus by direct immunofluorescence and viral isolation from samples of external genital lesions in a high prevalence population. J Clin Microbiol 1987; 25:323-6.
12. Ryncarz AJ, Goddard J, Wald A, Roizman B, Corey L. Development of a high throughput quantitative assay for detecting HSV DNA in clinical samples. J Clin Microbiol 1999; 37:1941-7.
13. Kuzushima K, Kudo T, Kimura H, et al. Prophylactic oral acyclovir in outbreaks of primary herpes simplex virus type 1 infection in a closed community. Pediatrics 1992; 89:379-83.
14. Sucato G, Wald A, Wakabayashi E, Vieira J, Corey L. Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region. J Infect Dis 1998; 177:1069-72.
15. Baird D, Wilcox A, Weinberg C. Use of time to pregnancy to study environmental exposures. Am J Epidemiol 1986; 124:470-80.
16. Gorbach PM, Galea JT, Amani B, et al. Don't ask, don't tell: patterns of HIV disclosure among HIV positive men who have sex with men with recent STI practising high risk behaviour in Los Angeles and Seattle. Sex Transm Infect 2004; 80:512-7.
17. Baird D, Weinberg C, Schwingl P, Wilcox A. Selection bias associated with contraceptive practice in time-to-pregnancy studies. Ann NY Acad Sci 1994; 709:156-64.
18. Basso O, Weinberg CR, Baird DD, Wilcox AJ, Olsen J. Subfecundity as a correlate of preeclampsia: a study within the Danish National Birth Cohort. Am J Epidemiol 2003; 157:195-202.
19. Henriksen T, Baird D, Olsen J, Hedegaard M, Secher N, Wilcox A. Time to pregnancy and preterm delivery. Obstet Gynecol 1997; 89:594-9.
20. Rowland AS, Baird DD, Weinberg CR, Shore DL, Shy CM, Wilcox AJ. Reduced fertility among women employed as dental assistants exposed to high levels of nitrous oxide. N Engl J Med 1992; 327:993-7.
21. Weinberg CR, Baird DD, Rowland AS. Pitfalls inherent in retrospective time-to-event studies: the example of time to pregnancy. Stat Med 1993; 12:867-79.
22. Weinberg CR, Baird DD, Wilcox AJ. Sources of bias in studies of time to pregnancy. Stat Med 1994; 13:671-81.
23. Langenberg A, Corey L, Ashley R, Leong W, Straus S. A prospective study of new infections with herpes simplex virus type land type 2. N Engl J Med 1999; 341:1432-8.
24. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116:197-202.
25. Bryson YJ, Dillon M, Bernstein DI, Radolf J, Zakowski P, Garratty E. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis 1993; 167:942-6.
26. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999; 282:331-40.
27. Crosby R, Sanders S, Yarber WL, Graham CA. Condom-use errors and problems: a neglected aspect of studies assessing condom effectiveness. Am J Prev Med 2003; 24:367-70.
28. Holmes K, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004; 82:454-61.
29. Mertz G, Ashley R, Burke R, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 1990; 161:653-60.
30. Edwards S, Carne C. Oral sex and the transmission of viral STIs. Sex Transm Infect 1998; 74:6-10.
31. Lafferty WE, Downey L, Celum C, Wald A. Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis 2000; 181:1454-7.
32. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003; 289:203-9.
33. Saracco A, Musicco M, Nicolosi A, et al. Man-to-woman sexual transmission of HIV: longitudinal study of 343 steady partners of infected men. J Acquir Immune Defic Syndr 1993; 6:497-502.
34. Musicco M, Lazzarin A, Nicolosi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med 1994; 154:1971-6.
35. Deschamps MM, Pape JW, Hafner A, Johnson WD Jr. Heterosexual transmission of HIV in Haiti. Ann Intern Med 1996; 125:324-30.
36. Padian N, Shiboski S, Glass S, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol 1997; 146:350-7.
37. Siddiqui NS, Brown LS Jr, Phillips RY, Vargas O, Makuch RW. No seroconversions among steady sex partners of methadone-maintained HIV-1-seropositive injecting drug users in New York City. AIDS 1992; 6:1529-33.
38. Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after first episode of genital herpes. Ann Intern Med 1992; 116:433-7.
39. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770-5.
40. Ashley RL. Sorting out the new HSV type specific antibody tests. Sex Transm Infect 2001; 77:232-7.
41. Frenkel LM, Garratty EM, Shen JP, Wheeler N, Clark O, Bryson YJ. Clinical reactivation of herpes simplex virus type 2 infection in seropositive pregnant women with no history of genital herpes. Ann Intern Med 1993; 118:414-8.
42. Langenberg A, Benedetti J, Jenkins J, Ashley R, Winter C, Corey L. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" HSV-2 infection. Ann Intern Med 1989; 110:882-7.
43. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic HSV-2 seropositive persons. N Engl J Med 2000; 342:844-50.
44. Brown ZA. HSV-2 specific serology should be offered routinely to antenatal patients. Rev Med Virol 2000; 10:141-4.
45. Wilkinson D, Barton S, Cowan F. HSV-2 specific serology should not be offered routinely to antenatal patients. Rev Med Virol 2000; 10:145-53.
46. Wilkinson D, Barton S, Chard S, Meadows J. The psychological consequences in patient undergoing a POCKit HSV-2 test. Int J STD AIDS 2000; 11:551-2.
47. Melville J, Sniffen S, Crosby R, et al. Psychosocial impact of serological diagnosis of herpes simplex virus type 2: a qualitative assessment. Sex Transm Infect 2003; 79:280-5.
48. Miyai T, Turner KR, Kent CK, Klausner J. The psychosocial impact of testing individuals with no history of genital herpes for herpes simplex virus type 2. Sex Transm Dis 2004; 31:517-21.
49. Meyer JL, Crosby RA, Whittington WL, et al. The psychosocial impact of serological herpes simplex type 2 testing in an urban HIV clinic. Sex Transm Infect 2005; 81:309-15.
50. Rosenthal SL, Zimet GD, Leichliter JS, et al. The psychosocial impact of serological diagnosis of asymptomatic herpes simplex type 2 infection. Sex Transm Infect 2006; 82:154-7.